# Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index

> **NCT02576080** · PHASE3 · UNKNOWN · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 80 (estimated)

## Conditions studied

- Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Imatinib
- **OTHER:** Surveillance

## Key facts

- **NCT ID:** NCT02576080
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10
- **Primary completion:** 2019-10
- **Final completion:** 2020-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2015-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576080, "Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02576080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*